Followers | 10 |
Posts | 1578 |
Boards Moderated | 0 |
Alias Born | 10/15/2014 |
Tuesday, May 10, 2016 9:20:50 AM
http://www.amcpmeetings.org/pdf/meetingabstracts.pdf
Subdermal Buprenorphine Implants Improve Societal Outcomes and Patient Morbidity and Mortality Relative to Sublingual Buprenorphine: Results of a Markov Model
BACKGROUND: Agonist therapy reduces cravings and relapse risk during recovery from opioid dependence. Fewer relapses equate to reduced societal consequences such as illicit drug use, disease transmission, criminal activity, mortality, and harm to community members. Sublingual buprenorphine+naloxone (SL-BPN), the standard-of-care in outpatient opioid dependence treatment, lacks intrinsic safeguards from diversion and non-adherence. Investigational subdermally implanted buprenorphine (BI, Probuphine) was more effective than SL-BPN in Phase-3 clinical trials, including a large double-blind, double-dummy trial in stable opioid-dependent patients. The extent that these clinical benefits translate into meaningful societal benefits has not been previously quantified.
OBJECTIVE: To assess the benefits of SD-BP from a societal perspective.
METHODS: Using Phase 3 clinical trial data of BI versus SL-BPN, a Markov model simulated monthly progression of nationally-representative cohorts through 5 health-states for 6 months: on agonist therapy (1) with and (2) without illicit drug use, discontinued therapy (3) with and (4) without illicit drug use, and (5) death. Each cycle applied health-state- and time-dependent risks of: opioid diversion and misuse, illicit drug use, accidental pediatric exposure, detox program entry, and death (suicide/drug-related non-suicide). Cohorts were derived from state-specific, agonist treatment utilization data. Model robustness was assessed by univariate and probabilistic sensitivity analyses.
RESULTS: BI was associated with an overall 45% reduction in treatment failure over 6 months of treatment. Modeled reductions in societal-level consequences were: opioid diversion and misuse (-92%), illicit drug use (-45%), accidental pediatric exposure (-98%), detox program entry (-80%), and drug-related death/suicide (-24%). A Statewise comparison demonstrated the greatest benefits for Pennsylvania and the fewest benefits for Idaho.
CONCLUSIONS: Benefits of BI vs. SL-BPN included improved morbidity/mortality and improved societal-level outcomes. Benefits were largely driven by the relative difficulty of diverting an implantable formulation. Patient-level benefits may be driven by the increased adherence and pharmacokinetic profile of the implants. While these results should be confirmed in subsequent studies, it can be conservatively concluded that BI treatment used for stable opioid dependent patients will have a positive societal benefit beyond the current standard of care.
SPONSORSHIP: Braeburn Pharmaceuticals.
Recent TTNP News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 12:32:38 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 08:23:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:22:56 PM
- Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. • GlobeNewswire Inc. • 08/19/2024 08:11:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2024 01:29:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 01:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 9:46 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM